Archemix Corp.   Report issue

For profit Phase 2
Founded: San Francisco CA United States (2000)
Status: Acquired by Baxalta (2010) → now Takeda (2018)

Organization Overview

First Clinical Trial
2006
NCT00432770
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

arc-1779 (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carotid Stenosis (Phase 2)

Embolism (Phase 2)

Intracranial Embolism (Phase 2)

Purpura (Phase 2)

Purpura, Thrombocytopenic (Phase 2)

Purpura, Thrombotic Thrombocytopenic (Phase 2)

Thromboembolism (Phase 2)

Thrombosis (Phase 1)

Thrombotic Microangiopathies (Phase 2)

Vascular Diseases (Phase 2)

von Willebrand Diseases (Phase 2)

von Willebrand Disease, Type 2 (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 1